Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the milan cancer institute

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 209-214

  Bonadonna, Gianni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PACLITAXEL;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; METASTASIS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 0029988598     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00612-5     Document Type: Article

References (31)

1. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992, 52, 2127-2137.
2. Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 1992, 52, 2371-2383.
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 1995, 332, 901-906.
4. Fisher B. The role of science in the evolution of breast cancer management. Heath Memorial Award Lecture. In Ames FC, Blumenschein GR, Montague ED, eds. Current Controversies in Breast Cancer. Austin, University of Texas Press, 1984, 1-21.
5. Martin DS, Fugman RA, Stolfi RL, et al. Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 1975, 5, 89-109.
6. Skipper HE, Schabel FM Jr. Tumor stem cell heterogeneity: implication with respect to the classification of cancers by chemotherapeutic effect. Cancer Treat Rep 1984, 68, 43-61.
7. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 1994, 330, 1253-1259.
8. Heppner GH. Tumor heterogeneity. Cancer Res 1984, 44, 2259-2265.
9. Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol 1986, 4, 244-257.
10. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995, 273, 542-547.
11. Bonadonna G, Valagussa P. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience. Surg Clin North America 1995, 4, 701-714.
12. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more axillary nodes involved. Five year results. J Clin Oncol, in press.
13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992, 339, 1-15, 71-85.
14. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995, 45, 227-243.
15. Bonadonna G, Valagussa P. Primary chemotherapy in operable breast cancer. Semin Oncol, in press.
16. Fisher B. Personal contributions to progress in breast cancer research and treatment. Semin Oncol, in press.
17. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983, 43, 1488-1492.
18. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979, 39, 3861-3865.
19. Gasparini G (guest ed.). Biological and clinical role of angiogenesis in breast carcinomas. Breast Cancer Res Treat 1995, 36, 103-261.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastatis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1-8.
21. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995, 1, 149-153.
22. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sd Am 1995, 1, 131-141.
23. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994, 12, 454-466.
24. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990, 82, 1539-1545.
25. Abeloff MD, Hayes DF, Henderson IC, et al. The current status of vinorelbine (Navelbine) in breast cancer. Semin Oncol 1995, 22 (Suppl 5), 1-87.
26. Rowinsky EK, Eisenhauer EA, Chaudhry U, et al. Paclitaxel (Taxol) Investigators' Workshop. Semin Oncol 1993, 20 (Suppl 3), 1-60.
27. Aapro MS, Lavelle F, Bissery MC, et al. The impact of docetaxel (Taxotere) on current treatment. Semin Oncol 1995, 22 (Suppl 4), 1-33.
28. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 1995, 13, 180-190.
29. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995, 87, 1169-1175.
30. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose- and sequence-finding study. J Clin Oncol 1995, 13, 2688-2699.
31. Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat, in press.